文献速递关节外科

全关节置换术中糖皮质激素的疗效与安全性:一项直接Meta分析

The Efficacy and Safety of Corticosteroids in Total Joint Arthroplasty: A Direct Meta-Analysis.
PubMed 文献 · J Arthroplasty · 2022-01-01

该研究检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials数据库中2020年2月前发表的文献,对23项研究进行直接比较Meta分析,评估初次全关节置换术中糖皮质激素的疗效与安全性。结果显示,术中地塞米松可减少术后疼痛、阿片类药物消耗及恶心呕吐,多剂量可进一步改善上述结局;关于围手术期不良事件风险证据不足。

要点

  • 术中地塞米松可减少初次全关节置换术后疼痛、阿片类药物消耗及恶心呕吐。
  • 多剂量地塞米松可进一步减少疼痛、阿片类药物消耗及恶心呕吐。
  • 围手术期地塞米松不良事件风险、最佳剂量及给药次数证据不足。

核心结论

  • 强证据支持使用单次或多次静脉地塞米松以减少初次全关节置换术后疼痛、阿片类药物消耗及恶心呕吐。
  • 围手术期地塞米松在初次全关节置换术中确定最佳剂量、给药次数或术后不良事件风险的证据不足。

研究设计与样本

  • 检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials数据库中2020年2月前发表的关于全关节置换术中糖皮质激素的研究。
  • 对纳入研究进行定性和定量同质性检验,随后进行系统综述和直接比较Meta分析。
  • 对1,581篇出版物进行批判性评价,最终纳入23项研究作为最佳可用证据进行分析。

主要发现

  • 术中地塞米松减少术后疼痛、阿片类药物消耗及恶心呕吐。
  • 多剂量地塞米松进一步减少疼痛、阿片类药物消耗及恶心呕吐。
  • 围手术期地塞米松在全关节置换术中不良事件风险的证据不足。

临床怎么用

  • 原文结论为强证据支持使用单次或多次静脉地塞米松以减少初次全关节置换术后疼痛、阿片类药物消耗及恶心呕吐。
  • 原文指出围手术期地塞米松确定最佳剂量、给药次数或术后不良事件风险的证据不足。

局限性

  • 围手术期地塞米松在全关节置换术中确定最佳剂量、给药次数或术后不良事件风险的证据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Corticosteroids are commonly used intraoperatively to treat pain and reduce opioid consumption and nausea associated with primary total joint arthroplasty (TJA). The purpose of this study was to evaluate the efficacy and safety of corticosteroids in primary TJA to support the combined clinical practice guidelines of the American Association of Hip and Knee Surgeons, American Academy of Orthopaedic Surgeons, Hip Society, Knee Society, and the American Society of Regional Anesthesia and Pain Management. METHODS: The MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases were searched for studies published before February 2020 on corticosteroids in TJA. All included studies underwent qualitative and quantitative homogeneity testing followed by a systematic review and direct comparison meta-analysis to assess the efficacy and safety of corticosteroids. RESULTS: Critical appraisal of 1,581 publications revealed 23 studies regarded as the best available evidence for analysis. Intraoperative dexamethasone reduces postoperative pain, opioid consumption, and nausea and vomiting. Multiple doses lead to further reduction in pain, opioid consumption, nausea and vomiting. There is insufficient evidence on the risk of adverse events with perioperative dexamethasone in TJA. CONCLUSION: Strong evidence supports the use of a single dose or multiple doses of intravenous dexamethasone to reduce postoperative pain, opioid consumption, nausea and vomiting after primary TJA. There is insufficient evidence on perioperative dexamethasone in primary TJA to determine the optimal dose, number of doses, or risk of postoperative adverse events.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Hannon CP, Fillingham YA, Mason JB, et al. The Efficacy and Safety of Corticosteroids in Total Joint Arthroplasty: A Direct Meta-Analysis. J Arthroplasty. 2022. PMID: 36162922. doi:10.1016/j.arth.2022.03.084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。